Sousa Santos F, et al. - In this analysis, researchers described their experience with sorafenib and sunitinib in the treatment of radioactive iodine (RAI)-refractory metastatic differentiated thyroid cancer (DTC) and assessed and compared their effectiveness and adverse effect profiles. In total, 28 individuals with RAI-refractory metastatic DTC were included. Data reported that mean progression-free survival was 10.8 months with sorafenib and 6 months with sunitinib as a second-line treatment. The authors discovered that the best overall response was partial remission (PR) with either agent – PR rate of 30.7% with sorafenib and 37.5% with second-line sunitinib. All treatment courses had registered adverse effects and cessation of definitive treatment was justified by 13.9%. Sorafenib and sunitinib tend to be effective treatment choices with an appropriate safety profile in slowing the progression of disease in patients with RAI-refractory metastatic DTC. Interestingly, even in patients experiencing disease progression on sorafenib, sunitinib seems to show some efficacy.